scPharmaceuticals to host KOL webinar on FUROSCIX use

scPharmaceuticals will host a KOL webinar focused on a nephrologist’s perspective on the use of FUROSCIX for treating fluid overload in heart failure and potential use for patients with chronic kidney disease on Tuesday, October 22, 2024 at 1:00 PM. The event will feature Dr. Michael Aaronson, MD. The FDA has assigned a PDUFA target action date of March 6, 2025, to consider scPharmaceuticals’ Supplemental New Drug Application seeking to expand the FUROSCIX indication to include the treatment of fluid overload in CKD. scPharmaceuticals’ management will also provide a corporate update focused on the company’s long-term growth initiatives, including the FDA-approved expansion of the FUROSCIX indication to include New York Heart Association Class IV heart failure patients, the potential expansion of the FUROSCIX indication to include treatment of fluid overload in CKD patients, and the ongoing development of a low volume autoinjector designed to provide physicians and patients with additional treatment flexibility.